Evidence map›Paper›PMID 29761661›Full record

ArticleCPT: pharmacometrics & systems pharmacology2018

How Do We "Validate" a QSP Model?

Daniel C Kirouac

Abstract readComment
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A Framework for Quantitative Systems Pharmacology Model Execution.Handbook of experimental pharmacology · 2025
    Review
  5. Towards a comprehensive assessment of QSP models: what would it take?Journal of pharmacokinetics and pharmacodynamics · 2024
    Review
  6. Assessing the performance of QSP models: biology as the driver for validation.Journal of pharmacokinetics and pharmacodynamics · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Pharmacometrics and/or Systems Pharmacology.CPT: pharmacometrics & systems pharmacology · 2019
    Article
  14. Pharmacodynamic Drug-Drug Interactions.Clinical pharmacology and therapeutics · 2019
    Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Daniel C KirouacApplied BioMath LLC, Oakland, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pancreatic NeoplasmsProteomicsDeoxycytidineDipeptidesGemcitabineHumansIndolesbirinapantDeoxycytidineDipeptidesGemcitabineIndoles

Identifiers

PMID29761661
PMCPMC6157666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.